Literaturverzeichnis zu Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkrankungen, 8. Aufl age - elsevier-data.de
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Literaturverzeichnis zu
Voderholzer, Hohagen (Hrsg.):
Therapie psychischer
Erkrankungen, 8. Auflage
1 Diagnostik und Therapie demenzieller Syndrome
1.1 Diagnostik demenzieller Syndrome guidelines for Alzheimer’s disease. Alzheimers Dement.
2011; 7: 263–9.
Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cog-
et al. The diagnosis of mild cognitive impairment due to nitive impairment to dementia – meta-analysis of 41 ro-
Alzheimer’s disease: recommendations from the National bust inception cohort studies. Acta Psychiatr Scand. 2009;
Institute on Aging-Alzheimer’s Association workgroups on 119: 252–265.
diagnostic guidelines for Alzheimer’s disease. Alzheimers Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D.
Dement. 2011; 7: 270–9. Depression and risk for Alzheimer disease: systematic re-
Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospi- view, metaanalysis, and metaregression analysis. Arch Gen
nal fluid and plasma biomarkers in Alzheimer disease. Nat Psychiatry 2006; 63: 530–538.
Rev Neurol. 2010; 6: 131–44. Patwardhan MB, McCrory DC, Matchar DB, Samsa GP, Rutsch-
Dubois B, Feldman HH, Jacova C, et al. Research criteria for mann OT. Alzheimer disease: operating characteristics of PET
the diagnosis of Alzheimer’s disease: revising the NINCDS – – a meta-analysis. Radiology. Apr 2004; 231(1): 73–80.
ADRDA criteria. Lancet Neurol 2007; 6: 734–746. Petersen RC, Roberts RO, Knopman DS, Boeve BF, Geda YE,
Dougall NJ, Bruggink S, Ebmeier KP. Systematic review of Ivnik RJ, Smith GE, Jack CR Jr. Mild cognitive impairment:
the diagnostic accuracy of 99mTc-HMPAOSPECT in de- ten years later. Arch Neurol. 2009 Dec; 66(12): 1447–55.
mentia. Am J Geriatr Psychiatry. 2004; 12: 554–570. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, et al.
Engelborghs S, De Vreese K, Van de Casteele T, et al. Diagnostic Toward defining the preclinical stages of Alzheimer’s di-
performance of a CSF-biomarker panel in autopsy-confirmed sease: recommendations from the National Institute on
dementia. Neurobiol Aging. Aug 2008; 29: 1 143–1 159. Aging-Alzheimer’s Association workgroups on diagnostic
Ferri CP, Prince M, Brayne C, et al. Global prevalence of de- guidelines for Alzheimer’s disease. Alzheimers Dement.
mentia: a Delphi consensus study. Lancet 2005; 366: 2 112– 2011; 7: 280–92.
2 117. Frölich L, Gutzmann H: Klinische Untersuchung Walker Z, Jaros E, Walker RW, Lee L, Costa DC, et al. De-
und Psychometrie. In: Förstl H (Hrsg.): Lehrbuch der Ge- mentia with Lewy bodies: a comparison of clinical diagno-
rontopsychiatrie. 2. Aufl. Stuttgart: Thieme 2003; 88–106. sis, FP-CIT single photon emission computed tomography
Frisoni GB, Hampel H, O’Brien JT, Ritchie K, Winblad B. Re- imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007;
vised criteria for Alzheimer’s disease: what are the lessons 78: 1176–81.
for clinicians? Lancet Neurol. 2011; 10(7): 598–601. Yuan Y, Gu ZX, Wei WS. Fluorodeoxyglucose-positron-emis-
Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J. Bio- sion tomography, single-photon emission tomography,
markers for Alzheimer’s disease: academic, industry and re- and structural MR imaging for prediction of rapid conver-
gulatory perspectives. Nat Rev Drug Discov. 2010; 9: 560–74. sion to Alzheimer disease in patients with mild cognitive
Jack CR Jr. Alliance for aging research AD biomarkers work impairment: a meta-analysis. AJNR Am J Neuroradiol
group: structural MRI. Neurobiol Aging. 2011; 32 Suppl 1: 2009; 30: 404–410.
S48–S57. Zakzanis KK, Graham SJ, Campbell Z. A meta-analysis of
Jorm AF, Jolley D. The incidence of dementia: A meta-analy- structural and functional brain imaging in dementia of the
sis. Neurology 1998; 51: 728–733. Alzheimer’s type: a neuroimaging profile. Neuropsychol
Jorm AF, Korten AE, Henderson AS. The prevalence of de- Rev. Mar 2003; 13(1): 1–18. Links: S3-Leitlinie Demenzen
mentia: A quantitative integration of the literature. Acta der DGN und der DGPPN: http: //www.dgn.org/images/sto-
Psychiatrica Scandinavica 1987; 76: 465–479. ries/dgn/leitlinien/ll–demenz/ll-demenz-lang-170210.pdf
Mattsson N, Zetterberg H, Hampel H, et al. CSF biomarkers
and incipient Alzheimer disease in patients with mild cog- 1.2 Therapie demenzieller Syndrome
nitive impairment. JAMA 2009; 302: 385–393.
McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakow-
CR Jr, et al. The diagnosis of dementia due to Alzheimer’s ski K, et al. Memantine in patients with Parkinson’s disease de-
disease: recommendations from the National Institute on mentia or dementia with Lewy bodies: a double-blind, place-
Aging-Alzheimer’s Association workgroups on diagnostic bo-controlled, multicentre trial. Lancet Neurol 2009; 8: 613–8.2 1 Diagnostik und Therapie demenzieller Syndrome Aisen PS, Schafer KA, Grundman M et al. Effects of rofecoxib Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hip- or naproxen vs placebo on Alzheimer disease progression: pisley-Cox J. Antidepressant use and risk of adverse outco- a randomized controlled trial. JAMA 2003; 289(21): 2 819– mes in older people: population based cohort study. Bmj 2 826. 2011; 343: d4551. Arzneimittelkommission der Deutschen Ärzteschaft: Emp- Cummings J. What Can Be Inferred from the Interruption of fehlungen zur Therapie der Demenz. 3. Aufl. 2004. the Semagacestat Trial for Treatment of Alzheimer’s Di- AWMF S3-Leitlinie IS. Hormontherapie in der Peri- und sease? Biol Psychiatry 2010; 68 (10): 876–8 Postmenopause (HT). AWMF 2009; 015/062 Birks J, Fli- Daiello LA, Ott BR, Lapane KL, Reinert SE, Machan JT, Dore cker L. Selegiline for Alzheimer’s disease. Cochrane Data- DD. Effect of discontinuing cholinesterase inhibitor thera- base Syst Rev 2003; (1): CD000442. py on behavioral and mood symptoms in nursing home Bachinskaya N, Hoerr R, Ihl R. Alleviating neuropsychiatric patients with dementia. Am J Geriatr Pharmacother 2009; symptoms in dementia: the effects of Ginkgo biloba extract Apr;7(2): 74–83. EGb 761. Findings from a randomized controlled trial. Deshmukh A, Ulveling K, Alla V, Abuissa H, Airey K. Prolon- Neuropsychiatr Dis Treat 2011; 7: 209–15. ged QTc interval and torsades de pointes induced by citalo- Ballard C, Creese B, Corbett A, Aarsland D. Atypical antipsy- pram. Tex Heart Inst J 2012; 39: 68–70. chotics for the treatment of behavioral and psychological Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt symptoms in dementia, with a particular focus on longer RD; Donepezil Study Group. Open-label, multicenter, pha- term outcomes and mortality. Expert Opin Drug Saf 2011; se 3 extension study of the safety and efficacy of donepezil 10: 35–43. in patients with Alzheimer disease. Arch Neurol 2001; Mar; Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, 58(3): 427–33. Kossakowski K, et al. The dementia antipsychotic withdra- Doody RS, Gavrilova SI, Sano M, rt al., on behalf of the dime- wal trial (DART-AD): long-term follow-up of a randomised bon investigators* Effect of dimebon on cognition, activi- placebo-controlled trial. Lancet Neurol 2009; 8: 151–7. ties of daily living, behaviour, and global function in pati- Ballard C, Kahn Z, Corbett A.Treatment of dementia with ents with mild-to-moderate Alzheimer’s disease: a rando- Lewy bodies and Parkinson’s disease dementia. Drugs mised, double-blind, placebo-controlled study. Lancet Aging 2011; Oct 1;28(10): 769–77. doi: 10.2165/11594110- 2008; 372: 207–215. 000000000-00000. Review. Egert S, Wagenpfeil S, Förstl H: Cholinesterase-Inhibitoren Ballard C, Lana MM, Theodoulou M, Douglas S, McShane R, und Alzheimer-Demenz: Metaanalysen zu Wirksamkeits- Jacoby R, et al. A randomised, blinded, placebo-controlled nachweis, Ursprung und Ergebnisverzerrung in publizier- trial in dementia patients continuing or stopping neurolep- ten Studien. Dtsch Med Wochenschr 2007; 132: 1 207– tics (the DART-AD trial). PLoS Med 2008; 5: e76. 1 213. Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin Emre M, Aarsland D, Albanese A et al. Rivastigmine for de- R, et al. Sertraline or mirtazapine for depression in demen- mentia associated with Parkinson’s disease. N Engl J Med tia (HTA-SADD): a randomised, multicentre, double- 2004; 351(24): 2 509–2 518. blind, placebo-controlled trial. Lancet 2011; 378: 403–11. Emre M, Tsolaki M, Bonuccelli U, Destee A, Tolosa E, Kutzel- Barak Y, Plopski I, Tadger S, Paleacu D. Escitalopram versus nigg A, et al. Memantine for patients with Parkinson’s di- risperidone for the treatment of behavioral and psychotic sease dementia or dementia with Lewy bodies: a rando- symptoms associated with Alzheimer’s disease: a rando- mised, double-blind, placebo-controlled trial. Lancet Neu- mized double-blind pilot study. Int Psychogeriatr 2011: 1–5. rol 2010; 9: 969–77. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Enache D, Winblad B, Aarsland D. Depression in dementia: Cochrane Database Syst Rev 2006; (1): CD005593. epidemiology, mechanisms, and treatment. Curr Opin Psy- Birks J, Grimley Evans J. Ginkgo biloba for cognitive impair- chiatry 2011; 24: 461–72. ment and dementia. Cochrane Database Syst Rev2009; Farlow M, Cummings J: Effective pharmacologic manage- (1):CD003120 Black SE, Doody R, Li H et al. Donepezil pre- ment of Alzheimer’s disease. The American Journal of Me- serves cognition and global function in patients with severe dicine 2007; 120: 388–397. Alzheimer disease. Neurology 2007; 69(5): 459–469. Farlow MR, Salloway S, Tariot PN, Yardley J, et al. Effectiven- Boothby LA, Doering PL. Vitamin C and vitamin E for ess and tolerability of high-dose (23 mg/d) versus stan- Alzheimer’s disease. Ann Pharmacother 2005; 39(12): dard-dose (10 mg/d) donepezil in moderate to severe 2 073–2 080. Alzheimer’s disease: A 24-week, randomized, double-blind Campbell N, Ayub A, Boustani MA, et al. Impact of cholines- study. Clin Ther. 2010 Jul;32(7): 1:234–51. terase inhibitors on behavioral and psychological symp- Farquhar C, Marjoribanks J, Lethaby A et al. Long term hor- toms of Alzheimer’s disease: a meta-analysis. Clinical In- mone therapy for perimenopausal and postmenopausal terventions in Aging 2008; 3(4): 719–728. women. Cochrane Database Syst Rev 2009;(2): CD004143. Carlsson CM, Gleason CE, et al.: Effects of simvastatin on ce- Fassbender K, et al. Therapie neurodegenerativer Demenzen. rebrospinal fluid biomarkers and cognition in middle-aged In: Diener HC, Putzki N: Leitlinien für die Diagnostik und adults at risk for Alzheimer’s disease. J Alzheimers Dis Therapie in der Neurologie. 4. überarb. Aufl. Stuttgart: 2008; 13: 187–197. Thieme; 2008.
1 Diagnostik und Therapie demenzieller Syndrome 3 FDA Drug Safety Communication (30.3.2012): Revised re- Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, commendations for Celexa (citalopram hydrobromide) re- Langley A, Pandita-Gunawardena ND, Hogg F, Clare C, lated to a potential risk of abnormal heart rhythms with Damms J. The efficacy of donepezil in the treatment of high doses. (http://www.fda.gov/Drugs/DrugSafety/ neuropsychiatric symptoms in Alzheimer disease. Neuro- ucm297391.htm) assessed 10.5.2012. logy 2004; 63(2): 214–9. Fioravanti M, Flicker L. Efficacy of nicergoline in dementia Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, et and other age associated forms of cognitive impairment. al. Donepezil and memantine for moderate-to-severe Cochrane Database Syst Rev 2001;(4): CD003159. Alzheimer’s disease. N Engl J Med 2012; Mar 8;366(10): Flicker L, Grimley Evans G. Piracetam for dementia or cogni- 893–903. tive impairment. Cochrane Database Syst Rev 2001;(2): Huybrechts KF, Gerhard T, Crystal S, Olfson M, Avorn J, Le- CD001011. vin R, et al. Differential risk of death in older residents in Foster JK, Verdile G, Bates KA, Martins RN. Immunization in nursing homes prescribed specific antipsychotic drugs: po- Alzheimer’s disease: naïve hope or realistic clinical potenti- pulation based cohort study. Bmj 2012; 344: e977. al? Mol Psychiatry 2009; 14: 239–251. Ihl R, Bachinskaya N, Korczyn AD, Vakhapova V, Tribanek Frölich L (2010) S3 Leitlinie Demenz – Symptomatische The- M, Hoerr R, Napryeyenko O; on behalf of the GOTADAY rapie der Demenzen. Nervenarzt Jun 2. [Epub ahead of Study Group. Efficacy and safety of a once-daily formulati- print] on of Ginkgo biloba extract EGb 761 in dementia with neu- Gabriel SR, Carmona L, Roque M et al. Hormone replace- ropsychiatric features: a randomized controlled trial; Inter- ment therapy for preventing cardiovascular disease in national Journal of Geriatric Psychiatry, Published online: post-menopausal women. Cochrane Database Syst Rev 7 DEC 2010, DOI: 10.1002/gps.2662. 2005; (2): CD002229. Ihl R, Tribanek M, Bachinskaya N. Efficacy and tolerability of Gaitan A, Garolera M, Cerulla N, Chico G, Rodriguez-Querol a once daily formulation of Ginkgo biloba extract EGb M, Canela-Soler J. Efficacy of an adjunctive computer- 761(R) in Alzheimer’s disease and vascular dementia: re- based cognitive training program in amnestic mild cogniti- sults from a randomised controlled trial. Pharmacopsychi- ve impairment and Alzheimer’s disease: a single-blind, atry 2012; 45: 41–6. randomized clinical trial. Int J Geriatr Psychiatry 2012 IQWiG. Cholinesterasehemmer bei Alzheimer Demenz. Ab- [Epub ahead of print]. schlussbericht A05–19A. Köln: Institut für Qualität und Gill SS, et al. Atypical antipsychotic drugs and risk of ischa- Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2007. emic stroke: population based retrospective cohort study. IQWiG. Ginkgohaltige Präparate bei Alzheimer Demenz. Ab- BMJ 2005; doi: 10.1136/bmj.38330. 470486.8F. schlussbericht A05–19B. Köln: Institut für Qualität und Graff MJ, Vernooij-Dassen MJ, Thijssen M, Dekker J, Hoefna- Wirtschaftlichkeit im Gesundheitswesen (IQWiG); 2008. gels WH, Rikkert MG. Community based occupational the- IQWiG. Nichtmedikamentöse Behandlung der Alzheimer rapy for patients with dementia and their care givers: ran- Demenz. Abschlussbericht A05–19D. Köln: Institut für domised controlled trial. Bmj 2006; 333: 1 196. Qualität und Wirtschaftlichkeit im Gesundheitswesen Gribbin J, Hubbard R, Gladman J, Smith C, Lewis S. Seroto- (IQWiG); 2009. ISSN: 1 864–2 500. nin-norepinephrine reuptake inhibitor antidepressants IQWiG. Memantin bei Alzheimer Demenz. Abschlussbericht and the risk of falls in older people: case-control and case- A05–19C. Köln: Institut für Qualität und Wirtschaftlich- series analysis of a large UK primary care database. Drugs keit im Gesundheitswesen (IQWiG); 2009. Aging 2011; 28: 895–902. IQWiG. Memantin bei Alzheimer Demenz. Arbeitspapier als Hausner L, Damian M, Sartoris A, Frölich L. Efficacy and co- Ergänzung zum Abschlussbericht A05–19C. Köln: Institut gnitive side-effects of ECT in depressed elderly with co- für Qualität und Wirtschaftlichkeit im Gesundheitswesen existing mild cognitive impairment or dementia. J Clin (IQWiG); 2011. Psychiatry 2011; 72 (1): 91–7. Isaac MG, Quinn R, Tabet N. Vitamin E for Alzheimer’s di- Herrmann N, Black SE, Chow T, Cappell J, Tang-Wai DF, sease and mild cognitive impairment. Cochrane Database Lanctot KL. Serotonergic Function and Treatment of Beha- Syst Rev 2008; (3): CD002854. vioral and Psychological Symptoms of Frontotemporal De- Jessen F, Maier W: Ein Beitrag zur aktuellen Antidementiva- mentia. Am J Geriatr Psychiatry 2011 [Epub ahead of print]. diskussion in Deutschland. Nervenarzt 2007; 78: 491–497. Heude B, Ducimetière P, Berr C. EVA Study. Cognitive decli- Kales HC, Kim HM, Zivin K, Valenstein M, Seyfried LS, Chi- ne and fatty acid composition of erythrocyte membranes: ang C, et al. Risk of mortality among individual antipsy- the EVA Study. AmJ Clin Nutr. 2003; 77(4): 803–808. chotics in patients with dementia. Am J Psychiatry 2012; Higgins JP, Flicker L. Lecithin for dementia and cognitive im- 169: 71–9. pairment. Cochrane Database Syst Rev 2003; (3): Kavirajan H, Schneider LS. Efficacy and adverse effects of CD001015. cholinesterase inhibitors and Memantinee in vascular de- Hogervorst E, Yaffe K, Richards M, Huppert F. Hormone re- mentia: a meta-analysis of randomised controlled trials. placement therapy to maintain cognitive function in wo- Lancet Neurol 2007; 6: 782–792. men with dementia. Cochrane Database Syst Rev 2002; (3): Kivipelto M, Ngandu T, Laatikainen T, et al. Risk score for CD003799. the prediction of dementia risk in 20 years among middle
4 1 Diagnostik und Therapie demenzieller Syndrome aged people: a longitudinal, population-based study. Lan- Pariente A, Fourrier-Réglat A, Bazin F, Ducruet T, Dartigues cet Neurol 2006; 5: 735–741. JF, Dragomir A, Perreault S, Moore N, Moride Y. Effect of Kurz A, Thone-Otto A, Cramer B, Egert S, Frolich L, Gertz treatment gaps in elderly patients with dementia treated HJ, et al. CORDIAL: Cognitive Rehabilitation and Cogniti- with cholinesterase inhibitors. Neurology 2012; Mar ve-behavioral Treatment for Early Dementia in Alzheimer 27;78(13): 957–63. Disease: A Multicenter, Randomized, Controlled Trial. Alz- Petersen RC, Thomas RG, Grundman M, Bennett D, et al.; heimer Dis Assoc Disord 2011 [Epub ahead of print]. Alzheimer’s Disease Cooperative Study Group. Vitamin E Laske CH, Morawetz C, Buchkremer G, Wormstall H: Prä- and Donepezil for the treatment of mild cognitive impair- ventive Maßnahmen bei demenziellen Erkrankungen. ment. N Engl J Med 2005; 352: 1–10. Dtsch Ärztebl 2005; 102: A1 446–1 453 (Heft 20). Qiu C, Kivipelto M, von Strauss E. Epidemiology of Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical Alzheimer’s disease: occurrence, determinants, and strate- activity on cognitive function in older adults at risk for gies toward intervention. Dialogues Clin Neurosci 2009; Alzheimer disease: a randomised trial. JAMA 2008; 300: 11: 111–128. 1 027–1 037. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, et al. Do- Lefevre G, Klingelhoefer L, Mollenhauer B, Kassubek J, cosahexaenoic acid supplementation and cognitive decline Ebersbach G, Tenenbaum N. Pharmacokinetics of Rivastig- in Alzheimer disease: a randomized trial. JAMA. 2010; mine Patch (Exelon) in Patients with Parkinson’s Disease 304(17): 1903–11. Dementia. 10th International Conference on Alzheimer’s Raina P, Santaguida P, Ismaila A, et al. Effectiveness of choli- and Parkinson’s Diseases AD/PD 2011; Abstract #334, nesterase inhibitors and Memantine for treating dementia: 2011. evidence review for a clinical practice guideline. Ann In- Lopez-Arrieta JM, Birks J. Nimodipine for primary degenera- tern Med. 2008; 148: 379–397. tive, mixed and vascular dementia. Cochrane Database Reines SA, Block GA, Morris JC, et al. Rofecoxib: no effect on Syst Rev 2002; (3): CD000147. Alzheimer’s disease in a 1-year, randomized, blinded, con- Luchsinger JA, et al.: Relation of higher folate intake to lower trolled study. Neurology 2004; 62(1): 66–71. risk of Alzheimer disease in the elderly. Arch Neurol 2007; Riepe MW, Sieber C, Frölich L, Haupt M. Alzheimer-Thera- 64: 86–92. pie: Ein Vorschlag für das ärztliche Vorgehen. Deutsches Liepelt I, Maetzler W, et al.: Behandlung der Demenz bei Par- Ärzteblatt 2008; 105: B1851–B1852. kinson-Syndromen. Nervenarzt 2008; 79: 36–46. Rieser S. Sturzprävention, Krafttraining mit 85. Deutsches Maidment I, Fox C, Boustani M. Cholinesterase inhibitors for Ärzteblatt 2007; 104: 1 524/Internet: www.aktivinjedemal- Parkinson’s disease dementia. Cochrane Database Syst Rev ter.de. 2006; (1): CD004747. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase Mangiolasche F, Solomon A, Winblad B, Mecocci P, Kivipelto inhibitors for dementia with Lewy bodies, Parkinson’s di- M. (2010) Alzheimer’s disease: clinical trials and drug de- sease dementia and cognitive impairment in Parkinson’s velopment. Lancet Neurol 9: 702–16. disease. Cochrane Database Syst Rev 2012; Mar 14;3: Martin BK, Szekely C, Brandt J et al. Cognitive function over CD006504. time in the Alzheimer’s Disease Antiinflammatory Prevention Rosenberg PB, Drye LT, Martin BK, Frangakis C, et al.; DI- Trial (ADAPT): results of a randomized, controlled trial of na- ADS-2 Research Group. Sertraline for the treatment of de- proxen and celecoxib. Arch Neurol 2008; 65(7): 896–905. pression in Alzheimer disease. Am J Geriatr Psychiatry. McKeith I, Del Ser T, et al. Efficacy of rivastigmine in demen- 2010 18(2): 136–45. tia with lewy bodies: a randomised, double blind, placebo- Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doo- controlled international study. Lancet 2000; 356: 2031– dy RS. Persistent treatment with cholinesterase inhibitors 2036. and/or memantine slows clinical progression of Alzheimer McShane R, Areosa Sastre A, Minakaran N. Memantine for disease. Alzheimers Res Ther 2009; Oct 21;1(2): 7. dementia. Cochrane Database Syst Rev 2006; (2): Schaefer EJ, Bongard V, Beiser AS, Lamon-Fava S, et al. Plas- CD003154. ma phosphatidylcholine docosahexaenoic acid content and Menge T, et al. Statine zur Behandlung von Erkrankungen des risk of dementia and Alzheimer disease: the Framingham zentralen Nervensystems. Nervenarzt 2005, 76: 426–437. Heart Study. Arch Neurol. 2006; 63(11): 1 545–1 550. Nelson JC, Devanand DP. A systematic review and meta-ana- Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of lysis of placebo-controlled antidepressant studies in people evidence for the efficacy of memantine in mild Alzheimer with depression and dementia. J Am Geriatr Soc 2011; 59: disease. Arch Neurol 2011; 68: 991–8. 577–85. Schwarz S, Frölich L, Deuschle M. Schlafstörungen im Alter. Olin J, Schneider L, Novit A, Luczak S. Hydergine for demen- Ein unterdiagnostiziertes und überbehandeltes Syndrom. tia. Cochrane Database Syst Rev 2001; (2): CD000359. Internist (Berl). 2010; 51(7): 914–22. Ondo WG, Shinawi L, Davidson A, Lai D. Memantine for Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Ro- non-motor features of Parkinson’s disease: a double-blind chon P. Antidepressants for agitation and psychosis in de- placebo controlled exploratory pilot trial. Parkinsonism mentia. Cochrane Database Syst Rev 2011: CD008191. Relat Disord 2011; 17: 156–9.
2 Alkoholabhängigkeit (ICD-10 F1) 5
Shumaker SA, Legault C, Kuller L, et al.; Women’s Health In- Werheid K, Thöne-Otto A: Kognitives Training bei Alzhei-
itiative Memory Study. Conjugated enquine estrogens and mer-Demenz. Nervenarzt 2006; 77: 549–557.
incidence of probable Dementia and mild cognitive im- Wilcock G, et al. Memantine for agitation/aggression and
pairment in postmenopausal women. JAMA 2004; 291: psychosis in moderately severe to severe Alzheimer Di-
2 947–2 958. sease: a pooled analysis of 3 studies. J Clin Psychiatry 2008;
Tabet N, Feldman H. Indomethacin for the treatment of 69: 341–348.
Alzheimer’s disease patients. Cochrane Database Syst Rev. Wild R, Pettit T, Burns A. Cholinesterase inhibitors for de-
2002; (2): CD003673. mentia with Lewy bodies. Cochrane Database Syst Rev
Tabet N, Feldman H. Ibuprofen for Alzheimer’s disease. 2003; (3): CD003672.
Cochrane Database Syst Rev. 2003; (2): CD004031. Winblad B, Grossberg G, Frölich L, et al. IDEAL, a 6-month,
Trifiro G, Gambassi G, Sen EF, Caputi AP, Bagnardi V, Brea J, double-blind, placebo-controlled study of the first skin
et al. Association of community-acquired pneumonia with patch for Alzheimer disease. Neurology 2007; 69 (Suppl 1):
antipsychotic drug use in elderly patients: a nested case- 14–22.
control study. Ann Intern Med 2010; 152: 418–25. Winblad B, Engedal K, Soininen H et al. A 1-year, rando-
Vieweg WV, Wood MA, Fernandez A, Beatty-Brooks M, Has- mized, placebo-controlled study of donepezil in patients
nain M, Pandurangi AK. Proarrhythmic risk with antipsy- with mild to moderate AD. Neurology 2001; 57(3): 489–
chotic and antidepressant drugs: implications in the elder- 495.
ly. Drugs Aging 2009; 26: 997–1 012. Winblad B, Jones RW, Wirth Y et al. Memantine in moderate
Vigen CL, Mack WJ, Keefe RS, Sano M, Sultzer DL, Stroup to severe Alzheimer’s disease: a meta-analysis of rando-
TS, et al. Cognitive effects of atypical antipsychotic medica- mised clinical trials. Dement Geriatr Cogn Disord 2007;
tions in patients with Alzheimer’s disease: outcomes from 24(1): 20–27.
CATIE-AD. Am J Psychiatry 2011; 168: 831–9. Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J,
Voigt-Radloff S, Graff M, Leonhart R, Schornstein K, Jessen Khan KM, et al. Meta-analysis of the impact of 9 medica-
F, Bohlken J, et al. A multicentre RCT on community occu- tion classes on falls in elderly persons. Arch Intern Med
pational therapy in Alzheimer’s disease: 10 sessions are not 2009; 169: 1952–60.
better than one consultation. BMJ Open 2011; 1: e000096. Yu F, Rose KM, Burgener SC, Cunningham C, Buettner LL,
Weintraub D, Rosenberg PB, Drye LT, Martin BK, et al.; DI- Beattie E, et al. Cognitive training for early-stage
ADS-2 Research Group. Sertraline for the treatment of de- Alzheimer’s disease and dementia. J Gerontol Nurs 2009;
pression in Alzheimer disease: week-24 outcomes. Am J 35: 23–9.
Geriatr Psychiatry. 2010; Apr;18(4): 332–40.
2 Alkoholabhängigkeit (ICD-10 F1)
Adams M, Effertz T. Volkswirtschaftliche Kosten des Alko- Aertgeerts B, Buntinx F, Ansoms S, Fevery J. Screening pro-
hol- und Tabakkonsums. In: Singer M, Batra, Mann K perties of questionnaires and laboratory tests for the detec-
(Hrsg.). Alkohol und Tabak. Grundlagen und Folgeerkran- tion of alcohol abuse or dependence in a general practice
kungen. Stuttgart–New York: Thieme; 2011, p. 57–62. population. Br J Gen Pract 2001; 51: 206–217.
Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi Allen NE, Beral V, Casabonne D, et al. Moderate alcohol in-
M, Janiri L, Agabio R, Colombo G, Gessa GL, Gasbarrini G. take and cancer incidence in women. J Natl Cancer Inst.
Baclofen efficacy in reducing alcohol craving and intake: a 2009; 101: 296–305.
preliminary double-blind randomized controlled study. Ansoms C, Deckers F, Lehert P, Pelc I, Potgieter A. An open
Alcohol Alcohol. 2002 37(5): 504–8. study with acamprosate in Belgium and Luxemburg: re-
Addolorato G, Leggio L, Ferrulli A, Cardone S, Bedogni G, sults on sociodemographics, supportive treatment and out-
Caputo F, Gasbarrini G, Landolfi R; Baclofen Study Group. come. Eur Addict Res 2000; 6: 132–140.
Dose-response effect of baclofen in reducing daily alcohol Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Di-
intake in alcohol dependence: secondary analysis of a ran- as JK. Naltrexone and cognitive behavioral therapy for the
domized, double-blind, placebo-controlled trial. Alcohol treatment of outpatient alcoholics: results of a placebo-
Alcohol. 2011; May-Jun 46(3): 312–317. controlled trial. Am J Psychiatry 1999; 156: 1 758–1 764.
Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonhia L, Mi- Aradottir S, Asanovska G, Gjerss S, Hansson P, Alling C.
rijello A, et al. Effectiveness and safety of baclofen for Phosphatidylethanol (PEth) concentrations in blood are
maintenance of alcohol abstinence in alcohol-dependent correlated to reported alcohol intake in alcohol-dependent
patients with liver cirrhosis: randomized, double-blind patients. Alcohol Alcohol 2006; 41: 431–437.
controlled study. The lancet 2007; 8: 1 915–1 922. Babor T, de la Fuente JR, Saunders J, Grant M. The Alcohol
Use Disorder Identification Test: Guidelines for use in pri-6 2 Alkoholabhängigkeit (ICD-10 F1) mary health care. Geneva: World Health Organisation; up (Munich Evaluation for Alcoholism Treatment, MEAT). 1992. Eur Arch Psychiatry Neurol Sci 1989; 239: 144–157. Berridge KC, Robinson TE. What is the role of dopamine in Galea S, Nandi A, Vlahov D. The social epidemiology of sub- reward: hedonic impact, reward learning, or incentive sali- stance use. Epidemiologic Reviews 2004; 26: 36–52. ence? Brain Research Reviews 1998; 28: 309–369. Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Brueck R, Mann K. Alkoholismusspezifische Psychotherapie. Flannery BA. Efficacy and safety of baclofen for alcohol de- Köln: Deutscher Ärzte-Verlag; 2006. pendence: a randomized, double-blind, placebo-controlled Bühringer G, Augustin R, Bergmann E, et al. Alkoholkonsum trial. Alcohol Clin Exp Res. 2010 Nov; 34(11): 1 849–1 857. und alkoholbezogene Störungen in Deutschland. Baden- Garbutt JC, Kranzler HR, O’Malley SS, et al. Efficacy and tole- Baden: Nomos; 2000. rability of long-acting injectable naltrexone for alcohol de- Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. pendence: a randomized controlled trial. JAMA 2005; 293: The AUDIT alcohol consumption questions (AUDIT-C): an 1 617–1 625. effective brief screening test for problem drinking. Ambu- Gastpar M, Bonnet U, Boening J, et al. Lack of efficacy of latory Care Quality Improvement Project (ACQUIP). Alco- naltrexone in the prevention of alcohol relapse: results hol Use Disorders Identification Test. Arch Intern Med from a German multicenter study. J Clin Psychopharmacol 1998; 158: 1 789–1 795. 2002; 22: 592–598. Clarke AS, Hedeker DR, Ebert MH, Schmidt DE, McKinney Gual A, He Y, Torup L, van den Brink W, Mann K. ESENSE WT, Kraemer GW. Rearing experience and biogenic amine 2: A Randomised, Double-blind, Placebo-controlled Study activity in infant rhesus monkeys. Biological Psychiatry of Nalmefene, As-needed Use in Alcohol Dependent Pati- 1996; 40: 338–352. ents. 35th Annual RSA Scientific Meeting 2012, San Fran- Colombo G, Vacca G, Serra S, Brunetti G, Carai MA, Gessa cisco. GL. Baclofen suppresses motivation to consume alcohol in Hartmann S, Aradottir S, Graf M, et al. Phosphatidylethanol rats. Psychopharmacology (Berl). 2003; May 167(3): 221– as a sensitive and specific biomarker: comparison with 224. gammaglutamyl transpeptidase, mean corpuscular volume Di Chiara G. The role of dopamine in drug abuse viewed from and carbohydrate-deficient transferrin. Addict Biol 2007; the perspective of its role in motivation. Drug Alcohol De- 12: 81–84. pend 1995; 38: 95–137. Heinz A, Higley JD, Gorey JG, Saunders RC, Jones DW, Diehl A, Croissant B, Batra M, Mundle G, Nakovics H, Mann Hommer D et al. In vivo association between alcohol into- K. Alcoholism in women: Is it different in onset and out- xication, aggression, and serotonin transporter availability come compared to men? European Archives of Psychiatry in nonhuman primates. Am J Psychiatry 1998; 155: 1 023– and Clinical Neurosciences 2007; 257: 344–351. 1 028. Diehl A, Mann K. Früherkennung von Suchtkrankheiten; Al- Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, koholprobleme identifizieren und Intervenieren. Deut- Hommer D et al. A relationship between serotonin trans- sches Ärzteblatt 2005; 102: 2 244–2 250. porter genotype and in vivo protein expression and alcohol Diehl A, Mann K. Pharmacological relapse prevention in al- neurotoxicity. Biol Psychiatry 2000; 47: 643–649. cohol and tobacco dependence. Internist 2007; 48: 79–88. Heinz A, Lober S, Georgi A, et al. Reward craving and with- Diehl A, Nakovics H, Croissant B, Reinhard I, Kiefer F, Mann drawal relief craving: assessment of different motivational K. Psychiatric liaison service in general hospitals: improve- pathways to alcohol intake. Alcohol 2003; 38: 35–39. ment in physicians’ detection rates of alcohol use disor- Heinz A, Reimold M, Wrase J, et al. Correlation of stable ele- ders. Psychosomatics 2009; 50(6): 599 604. vations in striatal (micro)-opioid receptor availability in Diehl A, Scherbaum N. Nicotine dependence as comorbidity detoxified alcoholic patients with alcohol craving: a posit- of alcohol dependence – epidemiology, etiology and thera- ron emission tomography study using carbon 11-labeled py. Fortschr Neurol Psychiatr 2007; 76: 14–18. carfentanil. Arch Gen Psychiatry 2005; 62: 57–64. Doudet D, Hommer D, Higley JD et al. Cerebral glucose me- Higley JD, Suomi SJ, Linnoila M. A nonhuman primate mo- tabolism, CSF 5-HIAA levels, and aggressive behavior in del of type II alcoholism? Part 2. Diminished social compe- rhesus monkeys. Am J Psychiatry 1995; 152: 1 782–1 787. tence and excessive aggression correlates with low cerebro- Driessen M, Veltrup C, Junghanns K, Przywara A, Dilling H. spinal fluid 5-hydroxyindoleacetic acid concentrations. Al- Costefficacy analysis of clinically evaluated therapeutic cohol Clin Exp Res 1996a; 20: 643–650. programs. An expanded withdrawal therapy in alcohol de- Higley JD, Suomi SJ, Linnoila M. A nonhuman primate mo- pendence. Nervenarzt 1999; 70: 463–470. del of type II excessive alcohol consumption? Part 1. Low Ehrenreich H, Jahn H, Heutelbeck K et al. ALITA – Neue We- cerebrospinal fluid 5-hydroxyindoleacetic acid concentra- ge in der ambulanten Intensivbehandlung von Alkoholab- tions and diminished social competence correlate with ex- hängigen. In: Mann K (Hrsg.): Neue Therapieansätze bei cessive alcohol consumption. Alcohol Clin Exp Res 1996b; Alkoholproblemen. Lengerich: Pabst 2002; 145–160. 20: 629–642. Feuerlein W, Kufner H. A prospective multicentre study of Higley JD, Suomi SJ, Linnoila M. CSF monoamine metabolite inpatient treatment for alcoholics: 18and 48-month follow- concentrations vary according to age, rearing, and sex, and
2 Alkoholabhängigkeit (ICD-10 F1) 7
are influenced by the stressor of social separation in rhesus Mann K, Agartz I, Harper C, et al. Neuroimaging in alcoho-
monkeys. Psychopharmacology 1991; 103: 551–556. lism: ethanol and brain damage. Alcohol Clin Exp 2001;
Hinckers AS, Laucht M, Schmidt MH, et al. Low level of res- Res 25: 104–109.
ponse to alcohol as associated with serotonin transporter Mann K, Baldström A, Torup L, Gual A, van den Brink W.
genotype and high alcohol intake in adolescents. Biol. Psy- Shifting the Paradigm: Reduction of Alcohol Consumption
chiatry 2006; 60: 282–287. in Alcohol Dependent Patients. Poster, EPA Congress
Hock B, Schwarz M, Domke I, et al. Validity of carbohydrate- 2012, Prague.
deficient transferrin (%CDT), gamma-glutamyltransferase Mann K, Hermann D. Individualised treatment in alcohol-
(gamma-GT) and mean corpuscular erythrocyte volume dependent patients. Eur Arch Psychiatry Clin Neurosci
(MCV) as biomarkers for chronic alcohol abuse: a study in 2010; 260: S116–S120.
patients with alcohol dependence and liver disorders of Mann K, Lober S, Croissant B, Kiefer F. Qualifizierte Ent-
non-alcoholic and alcoholic origin. Addiction 2005; 100: zugsbehandlung von Alkoholabhängigen: Ein Manual zur
1 477–1 486. Pharmako- und Psychotherapie. Köln: Deutscher Ärzte-
Hommer D, Momenan R, Kaiser E, Rawlings R. Evidence for Verlag; 2006.
a gender-related effect of alcoholism on brain volumes. Am Mann K, Schafer DR, Langle G, Ackermann K, Croissant B.
J Psychiatry 2001; 158: 198–204. The long-term course of alcoholism, 5, 10 and 16 years af-
Kiefer F, Jahn H, Tarnaske T, et al. Comparing and com- ter treatment. Addiction 2005b; 100: 797–805.
bining naltrexone and acamprosate in relapse prevention Mann K, Stetter F, Günthner A, Buchkremer G. Qualitätsver-
of alcoholism: a double-blind, placebo-controlled study. besserung in der Entzugsbehandlung von Alkoholabhängi-
Arch Gen Psychiatry 2003; 60: 92–99. gen. Dtsch Arztebl 1995; 92: 2 217–2 221.
Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dys- Mann K, Stetter F. Keine Entgiftung ohne psychotherapeuti-
regulation. Science 1997; 278: 52–58. sche Begleitung. Psycho 1991; 5: 296–304.
Kraus L, Bauernfeind R. Repräsentativerhebung zum Kon- Mann K. Pharmacotherapy of alcohol dependence: a review
sum psychotroper Substanzen bei Erwachsenen in of the clinical data. CNS Drugs 2004; 18: 485–504.
Deutschland 1997. Sucht 1998; 44: 3–82. Mayfield RD, Harris RA, Schuckit MA. Genetic factors influ-
Krupitsky EM, Burakov AM, Romanova TN, et al. Attenuati- encing alcohol dependence. Br J Pharmacol 2008; 154:
on of ketamine effects by nimodipine pretreatment in reco- 275–287.
vering ethanol dependent men: psychopharmacologic im- McBride WJ, Li TK. Animal models of alcoholism: neurobio-
plications of the interaction of NMDA and L-type calcium logy of high alcohol-drinking behavior in rodents. Crit Rev
channel antagonists. Neuropsychopharmacology 2001; 25: Neurobiol 1998; 12: 339–369.
936–947. Meyer C, Rumpf HJ, Hapke U, Dilling H, John U. Lebenszeit-
Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. prävalenz psychischer Störungen in der erwachsenen All-
Naltrexone in the treatment of alcohol dependence. N Engl gemeinbevölkerung. Nervenarzt 2000; 71: 535–542.
J Med 2001; 345: 1 734–1 739. Miller WR, Rollnick S. Motivational Interviewing: Preparing
Krystal JH, Petrakis IL, Mason G, Trevisan L, D’Souza DC. people to change addictive behaviour. New York: Guilford
Nmethyl-D-aspartate glutamate receptors and alcoholism: Press; 1991.
reward, dependence, treatment, and vulnerability. Phar- Miyakawa T, Yagi T, Kitazawa H, et al. Fyn-kinase as a deter-
macol Ther 2003; 99: 79–94. minant of ethanol sensitivity: relation to NMDA-receptor
Krystal JH, Petrakis IL, Webb E, et al. Dose-related ethanol- function. Science 1997; 278: 698–701.
like effects of the NMDA antagonist, ketamine, in recently Moyer A, Finney JW, Swearingen CE, Vergun P. Brief inter-
detoxified alcoholics. Arch Gen Psychiatry 1998; 55: 354– ventions for alcohol problems: a meta-analytic review of
360. controlled investigations in treatment-seeking and nont-
Krystal JH, Staley J, Mason G, et al. Gamma-aminobutyric reatment-seeking populations. Addiction 2002; 97: 279–
acid type A receptors and alcoholism: intoxication, depen- 292.
dence, vulnerability, and treatment. Arch Gen Psychiatry Newlin DB, Thomson JB. Alcohol challenge with sons of alco-
2006; 63: 957–968. holics: a critical review and analysis. Psychol Bull 1990;
Krystal JH, Tabakoff B. Ethanol abuse, dependence, and 108: 383–402.
withdrawal: neurobiology and clinical implications. In: Niaura RS, Rohsenow DJ, Binkoff JA, Monti PM, Pedraza M,
Psychopharmacology: a fifth generation of progress. Phila- Abrams DB. Relevance of cue reactivity to understanding
delphia: Lipincott, Williams & Wilkins 2002; 1 412–1 443. alcohol and smoking relapse. J Abnorm Psychol 1988; 97:
Küfner H. Therapieevaluation als Evidenzbasis der Suchtthe- 133–152.
rapie. Psychotherapie im Dialog 2003; 2: 170–177. O’Brien CP, Childress AR, Ehrman R, Robbins SJ. Conditio-
Mann K, Ackermann K, Croissant B, Mundle G, Nakovics H, ning factors in drug abuse: can they explain compulsion? J
Diehl A. Neuroimaging of gender differences in alcohol de- Psychopharmacol 1998; 12: 15–22.
pendence: are women more vulnerable? Alcohol Clin Exp O’Malley SS, Jaffe AJ, Chang G, et al. Six-month follow-up of
Res 2005a; 29: 896–901. naltrexone and psychotherapy for alcohol dependence.
Arch Gen Psychiatry 1996; 53: 217–224.8 2 Alkoholabhängigkeit (ICD-10 F1) O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Schuckit MA, Mazzanti C, Smith TL, et al. Selective genoty- Rounsaville B. Naltrexone and coping skills therapy for al- ping for the role of 5-HT2A, 5-HT2C, and GABA alpha 6 cohol dependence. A controlled study. Arch Gen Psychiat- receptors and the Serotonin transporter in the level of res- ry 1992; 49: 881–887. ponse to alcohol: a pilot study. Biol Psychiatry 1999; 45: Olfson M, Kessler RC, Berglund PA, Lin E. Psychiatric disor- 647–651. der onset and first treatment contact in the United States Schuckit MA, Smith TL, Kalmijn J. The search for genes con- and Ontario. Am J Psychiatry 1998; 155: 1 415–1 422. tributing to the low level of response to alcohol: Patterns of Oxenstierna G, Edman G, Iselius L, Oreland L, Ross SB, Sed- findings across studies. Alcoholism Clinical and Experi- vall G. Concentrations of monoamine metabolites in the mental Research 2004; 28: 1 449–1 458. cerebrospinal fluid of twins and unrelated individuals – a Schuckit MA, Smith TL. An 8-year follow-up of 450 sons of genetic study. J Psychiatr Res 1986; 20: 19–29. alcoholic and control subjects. Arch Gen Psychiatry 1996; Poikolainen K. Effectiveness of brief interventions to reduce 53: 202–210. alcohol intake in primary health care populations: a meta- Schultz W, Dayan P, Montague PR. A neural substrate of pre- analysis. Prev Med 1999; 28: 503–509. diction and reward. Science 1997; 275: 1 593–1 599. Pollock VE. Meta-analysis of subjective sensitivity to alcohol Schumann G, Saam C, Heinz A, Mann K, Treutlein J. Identifi- in sons of alcoholics. Am J Psychiatry 1992; 149: 1 534– kation von Risikogenen für Alkoholabhängigkeit – das 1 538. NMDARezeptor-System. Nervenarzt 2005; 76: 1 355–1 362. Project MATCH Research Group. Matching alcoholism treat- Seitz H, Bühringer G, Mann K. Empfehlungen des wissen- ments to client heterogeneity: project MATCH posttreat- schaftlichen Kuratoriums der DHS zu Grenzwerten für den ment drinking outcomes. J Stud Alcohol 1997; 58: 7–29. Konsum alkoholischer Getränke. SUCHT; 2006. Rist F, Demmel R, Hapke U, Kremer G, Rumpf HJ. Riskanter, Spanagel R, Herz A, Shippenberg TS. Opposing tonically acti- schädlicher und abhängiger Alkoholkonsum: Screening, ve endogenous opioid systems modulate the mesolimbic Diagnostik, Kurzintervention. Leitlinien der AWMF. Sucht dopaminergic pathway. Proc Natl Acad Sci USA 1992; 89: 2004; 2: 102–112. 2046–2050. Rist F, Scheuren B, Demmel R, Hagen J, Aulhorn I. Der Spanagel R, Mann K. Drugs for Relapse Prevention of Alco- Münsterer Alcohol Use Disorders Identification Test holism. Berlin: Birkhäuser; 2005. (AUDIT-G-M). In: Glöckner-Rist A, Rist F, Küfner H Spanagel R, Pendyala G, Abarca C, et al. The clock gene Per2 (Hrsg.): Elektronisches Handbuch zu Erhebungsinstru- influences the glutamatergic system and modulates alcohol menten im Suchtbereich. Mannheim: Zentrum für Umfra- consumption. Nat Med 2005; 11: 35–42. gen, Methoden und Analysen; 2003. Srisurapanont M, Jarusuraisin N. Opioid antagonists for al- Rollnick S, Mason P, Butler C. Health behaviour change: A cohol dependence. Cochrane Database Syst Rev 2005; guide for practitioners. Edinburgh: Curchill Livingstone; CD001867. 1999. Stetter F, Mann K. Dependency outcome of alcohol-depen- Room R, Babor T, Rehm J. Alcohol and public health. Lancet dent patients after inpatient detoxification and motivation 2005; 365: 519–530. treatment. Nervenarzt 1997; 68: 574–581. Rösner S, Hackl-Herrwerth A, Leucht S, Lehert P, Vecchi S, Suh JJ, Pettinati HM, Kampman KM, O’Brien CP. The status Soyka M. Acamprosate for alcohol dependence. Cochrane of disulfiram: a half of a century later. J Clin Psychophar- Database Syst Rev. 2010 Sep 8;(9):CD004332. Review. macol 2006; 26: 290–302. Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapa- Van den Brink W, Sörensen P, Torup L, Mann K, Gual A. nont M, Soyka M. Opioid antagonists for alcohol depen- Long-term Efficacy, Tolerability and Safety of Nalmefene dence. Cochrane Database Syst Rev. 2010, Dec 8; 12: As-needed in Alcohol-Dependence: A Randomised, Doub- CD001867. le-blind, Placebo-controlled Study. Poster, 35th Annual Rubak S, Sandbaek A, Lauritzen T, Christensen B. Motivatio- RSA Scientific Meeting 2012, San Francisco. nal interviewing: a systematic review and meta-analysis. Br Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP. Naltre- J Gen Pract 2005; 55: 305–312. xone in the treatment of alcohol dependence. Arch Gen Rumpf HJ, Hapke U, Hill A, John U. Development of a scree- Psychiatry 1992; 49: 876–880. ning questionnaire for the general hospital and general Volpicelli JR, Watson NT, King AC, Sherman CE, O’Brien CP. practices. Alcohol Clin Exp Res 1997; 21: 894–898. Effect of naltrexone on alcohol „high“ in alcoholics. Am J Rumpf HJ, Meyer C, Hapke U, Bischof G, John U. Inan- Psychiatry 1995; 152: 613–615. spruchnahme suchtspezifischer Hilfen von Alkoholabhän- WHO. The world health report 2003 – Shaping the future gigen und -missbrauchern: Ergebnisse der TACOS Bevöl- http://www.who.int/whr/2003/en/whr03_en.pdf kerungsstudie. Sucht 2000; 46: 9–17. Wienberg G. Versorgungsstrukturen von Menschen mit Al- Sass H, Soyka M, Mann K, Zieglgansberger W. Relapse pre- koholproblemen in Deutschland – eine Analyse aus Publi- vention by acamprosate. Results from a placebo-controlled cHealth-Perspektive In: Mann, K (Hrsg.): Neue Therapie- study on alcohol dependence. Arch Gen Psychiatry 1996; ansätze bei Alkoholproblemen 17–45. Lengerich–Berlin– 53: 673–680. Riga–Rom–Wien–Zagreb: Pabst 2002; 17–45.
3 Drogenabhängigkeit (ICD-10 F1) 9
Wiesbeck GA, Weijers HG, Lesch OM, Glaser T, Toennes PJ, Wise RA. The neurobiology of craving: implications for the
Boening J. Flupenthixol decanoate and relapse prevention understanding and treatment of addiction. J Abnorm Psy-
in alcoholics: results from a placebo-controlled study. Al- chol 1988; 97: 118–132.
cohol Alcohol 2001; 36: 329–334. Wrase J, Kahnt T, Schlagenhauf F, et al. Different neural sys-
Wilk AI, Jensen NM, Havighurst TC. Meta-analysis of rando- tems adjust motor behavior in response to reward and pu-
mized control trials addressing brief interventions in heavy nishment. Neuroimage 2007; 36: 1 253–1 262.
alcohol drinkers. J Gen Intern Med 1997; 12: 274–283.
3 Drogenabhängigkeit (ICD-10 F1)
3.1 Störungen durch Opiate rungen. Kapitel 3.2. „Akutbehandlung bei Störungen durch
Opioide“. Sucht 2002; 48: 245–264.
Bundesärztekammer. Richtlinien der Bundesärztekammer
zur Durchführung der substitutionsgestützten Behandlung 3.2 Störungen durch Kokain
Opiatabhängiger. Dtsch Ärztebl 2010; 107: A511–A516.
Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Amato L, Minozzi S, Pani PP, Solimini R, Vecchi S, Zuccaro
Otto MW. A meta-analytic review of psychosocial inter- P, Davoli M. Dopamine agonists for the treatment of cocai-
ventions for substance use disorders. Am J Psychiatry ne dependence. Cochrane Database Syst. Rev. 2011; Dec 7
2008; 165: 179–187. (12): CD003352.
Eap CB, Buclin T, Baumann P. Individual variability of the Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB,
clinical pharmacokinetics of methadone. Clin Pharmacoki- Otto MW. A meta-analytic review of psychosocial inter-
net 2002; 41: 1 153–1 193. ventions for substance use disorders. Am J Psychiatry
Europäische Beobachtungsstelle für Drogen und Drogen- 2008; 165: 179–187.
sucht: Stand der Drogenproblematik in Europa. Jahresbe- European Monitoring Centre for Drugs and Drug Addiction
richt 2005. 2007 selected issue: Cocaine and Crack Cocaine: a growing
Ferri M, Davoli M, Perucci CA. Heroin maintenance for public health issue. EU Publications Office.
chronic heroin-dependent individuals. Cochrane Database Karila L, Gorelick D, Weinstein A, et al. New treatments for
Syst. Rev. 2011 Dec 7;(12):CD003410. cocaine dependence: a focused review. Int J Neuropsycho-
Gelernter J, Kranzler HR. Genetics of addiction. In: Galanter pharmacol 2008; 11: 425–438.
M, Kleber HD (eds.). Textbook of Substance Abused Treat- O’Brien M, Anthony JC. Risk of becoming cocaine depen-
ment. 4th ed. Washington–London: American Psychiatric dent: epidemiological estimates for the US. Neuropsycho-
Publishing, 2008; pp. 17–27. pharmacology 2005; 30: 1 006–1 018.
Havemann-Reinecke U, Küfner H, Schneider U, Günthner A, Pabst A, Piontek D, Kraus L, Müller S. Substanzkonsum und
Schalast N, Vollmer HC. AWMF-Leitlinien: Postakutbe- substanzbezogene Störungen. Ergebnisse des Epidemiolo-
handlung bei Störungen durch Opioide. Sucht 2004; 50: gischen Suchtsurveys 2009. Sucht 2010; 56, 327–336.
226–257. Pani PP, Troqu E, Vecchi S, Amato L. Antidepressants for co-
Kendler K, Karkowski LM, Neale MC, Prescott LA. Illicit psy- caine dependence and problematic cocaine use. Cochrane
choactive substance use, heavy use, abuse, and depen- Database Syst. Rev. 2011; Dec 7(12): CD002950.
dence. Arch Gen Psychiatry 2000; 57: 261–269. Thomasius R, Gouzoulis-Mayfrank E, Karus C, et al. Psychi-
Kraus L, Augustin R, Orth B. Illegale Drogen, Einstiegsalter sche und Verhaltensstörungen durch Kokain, Amphetami-
und Trends. Ergebnisse des Epidemiologischen Suchtsur- ne, Ecstasy und Halluzinogene. Fortschr Neurol Psychiatr
vey 2003. Sucht 2005; 51 (Sonderheft 1): 19–28. 2004; 72: 679–95.
Kraus L, Pfeiffer-Gerschel T, Pabst A. Cannabis und andere
illegale Drogen: Prävalenz, Konsummuster und Trends. 3.3 Störungen durch Amphetamine und Ecstasy
Ergebnisse des Epidemiologischen Suchtsurveys 2006. American Psychiatric Association (APA). Practice guideline
Sucht 2008; 54 (Sonderheft 1): 16–25. for the treatment of patients with substance use disorders.
Kreek MJ, et al. Pharmacogenetics and human molecular ge- 2nd ed. In: American Psychiatric Association (APA).
netics of opiate and cocaine addictions and their treat- Practice Guidelines for the Treatment of Psychiatric Disor-
ments. Pharmacol Rev 2005; 57: 1–26. ders: Compendium 2006. Arlington, VA: American Psychi-
Pabst A, Piontek D, Kraus L, Müller S. Substanzkonsum und atric Association 2006; 291–563.
substanzbezogene Störungen. Ergebnisse des Epidemiolo- Baker A, Lee NK, Claire M, Lewin TJ, Grant T, Pohlman S,
gischen Suchtsurveys 2009. Sucht 2010; 56, 327–336. Saunders JB, Kay-Lambkin F, Constable P, Jenner L, Carr
Reymann G, Gastpar M, Tretter F, et al. AWMF-Leitlinien VJ. Brief cognitive behavioural interventions for regular
zur Diagnostik und Therapie von substanzbezogenen Stö-10 3 Drogenabhängigkeit (ICD-10 F1)
amphetamine users: a step in the right direction. Addiction 3.4 Störungen durch Cannabis
2005; 100: 367–378.
de Win MM, Jager G, Booij J, et al. Sustained effects of ecsta- American Psychiatric Association (APA). Practice guideline
sy on the human brain: a prospective neuroimaging study for the treatment of patients with substance use disorders.
in novel users. Brain 2008; 131: 2936–2945. 2nd ed. In: American Psychiatric Association (APA):
Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen Practice Guidelines for the Treatment of Psychiatric Disor-
J. Pharmacotherapy of Methamphetamine addiction: An ders: Compendium 2006. Arlington, VA: American Psychi-
Update. Substance Abuse 2008; 29: 31–49. atric Association 2006; 291–563. Available online at www.
Feeney GF, Connor JP, Young RM, Tucker J, McPherson A. psych.org/psych–pract/treatg/pg/SUD2ePG–04-28-06.pdf.
Improvement in measures of psychological distress Benyamina A, Lecacheux M, Blecha L, Reynaud M, Luka-
amongst amphetamine misusers treated with brief cogniti- siewcz M. Pharmacotherapy and psychotherapy in canna-
ve-behavioural therapy (CBT). Addict Behav 2006; 31: bis withdrawal and dependence. Expert Rev Neurother
1 833–1 843. 2008; 8: 479–491.
Gouzoulis-Mayfrank E, Daumann J. Neurotoxicity of methy- BzgA – Bundeszentrale für gesundheitliche Aufklärung. Die
lenedioxyamphetamines (MDMA; Ecstasy) in humans: Drogenaffinität Jugendlicher in der Bundesrepublik
how strong is the evidence? Addiction 2006; 101: 348–361. Deutschland 2008. Alkohol-, Tabak- und Cannabiskon-
Gouzoulis-Mayfrank E, Daumann J. Neurotoxicity of drugs sum. Erste Ergebnisse zu aktuellen Entwicklungen und
of abuse – the case of methylenedioxyamphetamines (MD- Trends. Köln, BzgA; 2008.
MA; ecstasy) and amphetamines. Dialogues in Clinical Cannabisbezogene Störungen. In: Schmidt L, Kaspar M, Fal-
Neuroscience 2009; 11: 305–317. kai P, Gaebel J (Hrsg.): Evidenzbasierte Suchtmedizin. Be-
Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, handlungsleitlinie Substanzbezogene Störungen der DG-
Batki SL. Pharmacological approaches to methamphetami- Sucht und DGPPN. Deutscher Ärzteverlag 2006; 143–170.
ne dependence: a focused review. Br J Clin Pharmacol Denis C, Lavie E, Fatseas M, Auriacombe M. Psychothera-
2010; 69: 578–592. peutic interventions for cannabis abuse and/or dependence
King GR, Ellinwood EH. Amphetamines and other stimu- in outpatient settings. Cochrane Database of Systematic
lants. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG Reviews, 2006.
(eds.): Substance Abuse: A Comprehensive Textbook. 4th European Monitoring Center for Drugs and Drug Addiction.
ed. Baltimore: Lippincott Williams & Wilkins 2004; 277– Annual Report 2010. The State of the drugs problem in Eu-
301. rope. Lisbon: EMCDDA, 2010.
Kraus L, Augustin R, Orth, B. Illegale Drogen, Einstiegsalter Hoch E, Zimmermann P, Henker J, Rohrbacher H, Noack R,
und Trends. Ergebnisse des Epidemiologischen Suchtsur- Bühringer G, Wittchen HU. Modulare Therapie von Can-
vey 2003. Sucht 2005; 51: S1: S19–S28. nabisstörungen: Das CANDIS-Programm. Göttingen: Ho-
Longo M, Wickes W, Smout M, Harrison S, Cahill S, White grefe-Verlag, 2011.
JM. Randomized controlled trial of dexamphetamine Hoch E, Noack R, Henker J, Pixa A, Hofler M, Behrendt S,
maintenance for the treatment of methamphetamine de- Buhringer G, Wittchen HU. Efficacy of a targeted cogniti-
pendence. Addiction 2010; 105: 146–154. ve-behavioral treatment program for cannabis use disor-
Thomasius R, Gouzoulis-Mayfrank E. Psychische und verhal- ders (CANDIS). Eur Neuropsychopharmacol 2012; 22:
tensbezogene Störungen durch Kokain, Amphetamine, Ec- 267–280.
stasy und Halluzinogene. In: Schmidt LG, Gastpar M, Fal- Levin FR, Mariani JJ, Brooks DJ, Pavlicova M, Cheng W,
kai P, Gaebel W (Hrsg.): Evidenzbasierte Suchtmedizin. Nunes EV. Dronabinol for the treatment of cannabis de-
Behandlungsleitlinie Substanzbezogene Störungen der DG- pendence: a randomized, double-blind, placebo-controlled
Sucht und DGPPN. Deutscher Ärzteverlag 2006; 241–270. trial. Drug Alcohol Depend 2011; 116: 142–150.
Tiihonen J, Kuoppasalmi K, Fohr J, Tuomola P, Kuikanmaki Kraus L, et al.: Cannabis und andere illegale Drogen: Präva-
O, Vorma H, Sokero P, Haukka J, Meririnne E. A compari- lenz, Konsummuster und Trends. Ergebnisse des Epide-
son of aripiprazole, methylphenidate, and placebo for am- miologischen Suchtsurveys 2006. Sucht 2008; 54 (Sonder-
phetamine dependence. Am J Psychiatry 2007; 164: 160– heft 1): S16–25.
162. Kraus L. Epidemiologie des Cannabiskonsum von Jugendli-
Tiihonen, J, Krupitsky, E, Verbitskaya, E, Blokhina, E, Ma- chen und Erwachsenen. Stuttgart: Fachtagung Cannabis
montova, O, Fohr, J, Tuomola, P, Kuoppasalmi, K, Kivinie- 2005.
mi, V, Zwartau, E. Naltrexone implant for the treatment of Kraus L, Augustin R, Orth, B. Illegale Drogen, Einstiegsalter
polydrug dependence: a randomized controlled trial. Am J und Trends. Ergebnisse des Epidemiologischen Suchtsur-
Psychiatry 2012; 169: 531–536. veys 2003. Sucht 2005; 51, S1: S19–S28.
Vocci FJ, Montoya ID. Psychological treatments for stimulant Moore T, et al. Cannabis use and risk of psychotic or affective
misuse, comparing and contrasting those for amphetamine mental health outcomes: a systematic review. The Lancet
dependence and those for cocaine dependence. Curr Opin 2007; 3: 319–328.
Psychiatry 2009; 22: 263–268. NICE, National Institute for Health and Clinical Excellence
Guideline 51, Drug Misuse: Psychosocial Interventious.
NICE, London, 2007.4 Benzodiazepinabhängigkeit (ICD-10 F.13.2) 11
Perkonigg A, Lieb R, Höfler M, Schuster P, Sonntag H, Witt- Thomasius R, Gouzoulis-Mayfrank E. Psychische und verhal-
chen H-U. Patterns of cannabis use, abuse and dependence tensbezogene Störungen durch Kokain, Amphetamine, Ec-
over time: incidence, progression and stability in a sample stasy und Halluzinogene. In: Schmidt LG, Gastpar M, Fal-
of 1228 adolescents. Addiction 1999; 94: 1 663–1 678. kai P, Gaebel W (Hrsg.): Evidenzbasierte Suchtmedizin.
Pfeiffer-Gerschel T, Kipke I, Flöter S, Lieb C, Raiser P. Bericht Behandlungsleitlinie Substanzbezogene Störungen der DG-
REITOX-Knotenpunkts Deutschland an die EBDD. Neue Sucht und DGPPN. Deutscher Ärzteverlag 2006; 241–270.
Entwicklungen, Trends und Hintergrundinformation zu
Schwerpunktthemen. München: Institut für Therapiefor- 3.6 Komorbidität
schung, 2009.
Drake RE, O’Neal EL, Wallach MA. A systematic review of
Pope HG jr, Gruber AJ, Hudson JI, Cohane G, Huestis MA,
psychosocial research on psychosocial interventions for
Yurgelun-Todd D. Early-onset cannabis use and cognitive
people with co-occurring severe mental and substance use
deficits: what is the nature of the association? Drug Alcohol
disorders. J Subst Abuse Treat 2008; 34: 123–138.
Depend 2003; 69: 303–310.
Gouzoulis-Mayfrank E. Komorbidität Psychose und Sucht –
Pope HG jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-
Grundlagen und Praxis. Mit Manualen für die Psychoedu-
Todd D. Neuropsychological performance in long-term
kation und Verhaltenstherapie. 2. erw. Aufl. Darmstadt:
cannabis users. Arch Gen Psychiatry 2001; 56: 909–915.
Steinkopff; 2007.
Vandrey R, Haney M. Pharmacotherapy for cannabis depen-
Moggi F. Etiological theories on the relationship of mental
dence: how close are we? CNS Drugs 2009; 23: 543–553.
disorders and substance use dirorders. In: Stohler R, Röss-
Zudnick S, Schneider U, Leweke M, Jülicher A, Tossmann P,
ler W (eds.). Dual diagnosis. The evolving conceptual
Bonnet U. Studienlage zur Behandlung der Cannabisab-
framework. Basel: Karger 2005; 1–14.
hängigkeit. Fortschr Neurol Psychiat 2006; 74: 211–225.
Murthy P, Chand P. Treatment of dual diagnosis disorders.
3.5 Störungen durch Halluzinogene Curr Opin Psychiatry 2012; 25: 194–200.
Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental
Kraus L, Augustin R, Orth B. Illegale Drogen, Einstiegsalter disorders with alcohol and other drug abuse. Results from
und Trends. Ergebnisse des Epidemiologischen Suchtsur- the Epidemiologic Catchment Area (ECA) Study. JAMA
vey 2003. Sucht 2005; 51, S1: S19–S28. 1990; 264: 2 511–2 518.
Pechnick RN, Ungerleider JT. Hallucinogens. In: Lowinson Stohler R, Rössler W (eds.). Dual Diagnosis. The Evolving
JH, Ruiz P, Millman RB, Langrod JG (eds.): Substance abu- Conceptual Framework. Basel: Karger; 2005.
se: a comprehensive textbook. 4th ed. Baltimore: Lip- Wilens TE. Pharmacotherapy of ADHD in adults. CNS Spectr
pincott Williams & Wilkins 2004; 313–323. 2008; 13 (5 Suppl 8): 11–13.
4 Benzodiazepinabhängigkeit (ICD-10 F.13.2)
Ashton H. ’Benzodiazepine abuse’, in Caan W, De Belleroche Fach M, Bischoff G, Schmidt C, Rumpf HJ. Prevalence of de-
J (eds.). Drink, drugs and dependence: from science to cli- pendence on prescription drugs and associated mental dis-
nical practice, London: Routledge 2002. orders in a representatitve sample of general hospital pati-
Benkert O, Hippius H. Kompendium der Psychiatrischen ents. Gen Hosp Psychiatry 2007; 29: 257–263.
Pharmakotehrapie, 4. Aufl. Springer: Berlin, Heidelberg Gerra G, Zaimovic A, Guisti F, Moi G, Brewer C. Intravenous
2003. flumazenil versus oxazepam tapering in the treatment of
Bobes J, Rubio G, Teran A, Cervera G, Lopez-Gomez V, Vilar- benzodiazepine withdrawal: a randomized, placebo-cont-
daga I, Perez M. Pregabalin for the discontinuation of rolled study. Addict Biol 2002; 7: 385–395.
long-term benzodiazpines use: an assessment of its effec- Glaeske G. Medikamente – Psychotrope und andere Arznei-
tiveness in daily clinical practice. Eur Psychiatry 2012; 27: mittel mit Missbrauchs- und Abhängigkeitspotenzial. In:
301–307. DHS (Hrsg.). Jahrbuch Sucht 10. Geesthacht: Neuland
de las Cuevas, C, Sanz E, de la Fuente J. Benzodiazepines: 2010, S. 69–95.
more “behavioural” addiction than dependence. Psycho- Hibell B, Andersson B, Bjarnasson T et al. The ESPAD report
pharmacology 2003; 167: 297–303 2003: alcohol and other drug use among students in 35 Eu-
Denis C, Fatseas M, Lavie E, Auriacombe M. Pharmacologio- ropean countries, the Swedish Council for Information on
cal interventions for benzodiazepine management in out- Alcohol and Other Drugs (CAN) and Council of Europe
patient settings. Cochrane Database Syst Rev 2006; 3: Pompidou Group. 2004.
CD005194. Hood S, O’Neill G, Hulse G. The role of flumazenil in the
EMCDDA. Sexual assaults facilitated by drugs or alcohol. treatment of benzodaizepine dependence: physiological
EMCDDA Technical Data Sheet 2008 (http://www.emcdda. and psychological profiles. J Psychopharmacol 2009; 23:
europa.eu/html.cfm/index50537EN.html). 401–409.You can also read
